Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™
Virpax Pharmaceuticals Reports 2023 Year-End Results
Scilex Entered into a Agreement with Virpax Pharmaceuticals
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price
PALO ALTO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, œScilex or œCompany), an innovative revenue-generating company focused on acquiring, developing and...
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study
MILAN--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced the completion of patient enrollment in study 008A, its potentially pivotal study with evenamide in patients suffering from schizophrenia.
Virpax Pharmaceuticals Announces Leadership Transition
Virpax Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing